Compare PDLB & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | STRO |
|---|---|---|
| Founded | 1960 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.9M | 85.0M |
| IPO Year | 2021 | N/A |
| Metric | PDLB | STRO |
|---|---|---|
| Price | $16.45 | $25.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | 64.4K | ★ 139.7K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 206.67 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.88 | $0.52 |
| 52 Week High | $18.01 | $25.68 |
| Indicator | PDLB | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 77.95 |
| Support Level | $15.83 | $0.76 |
| Resistance Level | $17.29 | N/A |
| Average True Range (ATR) | 0.40 | 2.05 |
| MACD | -0.03 | 0.46 |
| Stochastic Oscillator | 38.53 | 92.12 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.